Selexipag

Selexipag

Names
IUPAC name 2-{4-[(5,6-diphenylpyrazin-2-yl)(propan-2-yl)amino]butoxy}-N-(methanesulfonyl)acetamide
Identifiers
CAS Registry Number	475086-01-2 Y
ChEMBL	ChEMBL238804 N
ChemSpider	8089417 Y
InChI InChI=1S/C26H32N4O4S/c1-20(2)30(16-10-11-17-34-19-24(31)29-35(3,32)33)23-18-27-25(21-12-6-4-7-13-21)26(28-23)22-14-8-5-9-15-22/h4-9,12-15,18,20H,10-11,16-17,19H2,1-3H3,(H,29,31) Y Key: QXWZQTURMXZVHJ-UHFFFAOYSA-N Y InChI=1/C26H32N4O4S/c1-20(2)30(16-10-11-17-34-19-24(31)29-35(3,32)33)23-18-27-25(21-12-6-4-7-13-21)26(28-23)22-14-8-5-9-15-22/h4-9,12-15,18,20H,10-11,16-17,19H2,1-3H3,(H,29,31) Key: QXWZQTURMXZVHJ-UHFFFAOYAA
Jmol-3D images	Image
KEGG	D09994 Y
PubChem	9913767
SMILES CC(C)N(CCCCOCC(=O)NS(=O)(=O)C)C1=CN=C(C(=N1)C2=CC=CC=C2)C3=CC=CC=C3
UNII	5EXC0E384L Y
Properties
Chemical formula	C26H32N4O4S
Molar mass	496.6 g·mol−1
Except where noted otherwise, data is given for materials in their standard state (at 25 °C (77 °F), 100 kPa)
N verify (what is: Y/N?)
Infobox references

Selexipag (ACT-293987, NS-304) is a drug currently in development by Actelion as a treatment of pulmonary arterial hypertension. Selexipag and its active metabolite, ACT-333679, are agonists at the PGI₂ prostaglandin receptor, which leads to vasodilation in the pulmonary circulation.^[1]

References

1. ↑ Sitbon, O.; Morrell, N. (2012). "Pathways in pulmonary arterial hypertension: The future is here". European Respiratory Review 21 (126): 321–327. doi:10.1183/09059180.00004812. PMID 23204120.